Article Text

Download PDFPDF
Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer
  1. Mengjun Zhang, MD*,
  2. Tianbo Liu, PhD*,
  3. Bairong Xia, PhD*,
  4. Chunyan Yang, PhD,
  5. Siyu Hou, MD*,
  6. Wanlin Xie, MD and
  7. Ge Lou, PhD*
  1. *Department of Gynecology, Harbin Medical University Cancer Hospital;
  2. Department of Epidemiology and Biostatistics, School of Public Health, Harbin Medical University; and
  3. Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China.
  1. Address correspondence and reprint requests to Ge Lou, PhD, Department of Gynecology, Tumor Hospital of Harbin Medical University, 6 Baojian Rd, Harbin 150040, China. E-mail: louge_tuo


Objective This study aimed to investigate whether platelet-derived growth factor D (PDGF-D) is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, which has not been studied by others previously.

Methods In this study, we detected expression of PDGF-D in ovarian cancer tissues through immunohistochemistry and Western blotting. Furthermore, we analyzed the association between PDGF-D expression and clinicopathological features including prognosis in epithelial ovarian cancer. Statistical analyses were performed by using χ2 test, log-rank test, Cox regression test, and Kaplan-Meier method.

Results High PDGF-D expression is positively correlated with International Federation of Gynecology and Obstetrics stage (P < 0.001), histologic grade (P < 0.001), lymph node metastasis (P = 0.022), and poor prognosis (P < 0.001). Platelet-derived growth factor D in platinum-resistant cases is overexpressed compared with that in platinum-sensitive cases (P < 0.001). Obstetrics stage (P = 0.029) and PDGF-D overexpression (P < 0.001) are independently correlated with platinum resistance.

Conclusions Our study indicates that PDGF-D overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy and poor prognosis.

  • Epithelial ovarian cancer
  • Platelet-derived growth factor D
  • Platinum resistance
  • Prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • This study was supported by a grant from the National Natural Science Foundation of China (no. 81472028), the National Natural Science Foundation of China (no. 81502225), the Postdoctoral Foundation of China (no. 2015M581480), the Postdoctoral Foundation of Heilongjiang Province of China (no. LBH-Z15123), the Haiyan Foundation of the Affiliated Tumor Hospital of Harbin Medical University (no. JJMS2016-01), the Fundamental Research Funds for the Provincial Universities (no. 2016lczx77), and the Youth Elite Training Foundation of the Affiliated Tumor Hospital of Harbin Medical University (no. JY2016-03).

  • The authors declare no conflicts of interest.

  • M.Z. and T.L. contributed equally to this article.